Wells Fargo Upgrades Biogen to Overweight From Equalweight, Adjusts PT to $250 From $200

Wells Fargo has upgraded Biogen’s stock rating from Equalweight to Overweight and increased its price target from $200 to $250. This positive change reflects a more optimistic outlook on the pharmaceutical company’s future performance. The article also lists recent analyst recommendations and news related to Biogen.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin